CAR-T biotech Caribou weighs its options after struggling to find funding

Caribou Biosciences said Tuesday it is shelving two allogeneic CAR-T cell therapy programs and heading for the exit after failing to secure funding to continue its work. The California biotech is discontinuing vispa-cel for relapsed ...